Sichuan Credit Pharmaceutical Co. Ltd. has described cocrystals of tizanidine and meloxicam reported to be useful for the treatment of pain.

Haisco Pharmaceutical Group Co. Ltd. has divulged cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of inflammatory, renal, psychiatric, cardiovascular, eye, respiratory and metabolic disorders, as well as cancer.

Hangzhou Baicreat Pharma-Tech Co. Ltd. has identified DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Nanjing Nuoyuan Medical Devices Co. Ltd. has synthesized heptamethine cyanine near infrared (NIR) dyes reported to be useful for diagnosis of cancer.

Shanghai Apeiron Biotechnology Co. Ltd. has disclosed proteolysis targeting chimeras (PROTACs) reported to be useful for the treatment of cancer.

Scientists at Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shanghai Senhui Pharmaceutical Co. Ltd. and Shanghai Shengdi Pharmaceutical Co. Ltd. have described benzene ring derivatives acting as GABA-A receptor agonists reported to be useful for anesthesia and for the treatment of anxiety disorders, insomnia, depression, nausea and vomiting, migraine, convulsions, schizophrenia and epilepsy.

Researchers at China Pharmaceutical University and Chongqing Innovation Institute, China Pharmaceutical University have divulged ubiquitin C-terminal hydrolase 7 (USP7; HAUSP) inhibitors reported to be useful for the treatment of inflammatory disorders, infections and cancer.

Shaoxing City Youluofei Pharmaceutical Co. Ltd. has identified adenosine receptor ligands reported to be useful for the treatment of cancer, diabetes, pain, neuroinflammation, metabolic diseases, cardiovascular diseases, respiratory disorders and inflammatory disorders, among others.

Beijing Innocare Pharma Tech Co. Ltd. has synthesized E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.

Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed non-receptor tyrosine-protein kinase TYK2 inhibitors and/or degradation inducers reported to be useful for the treatment of psoriasis, cancer, rheumatoid arthritis, asthma and more.